美国丙型肝炎消除计划的障碍与机遇

摘要/Abstract

摘要： 丙型肝炎病毒(HCV)感染是全球重要的公共卫生问题,是导致肝硬化、肝细胞癌的(HCC)主要原因之一。由于高效抗病毒药物的出现和RNA检测技术的发展,实现HCV的消除是有望达成的目标。本文聚焦于美国肝病学会(AASLD)和美国感染病学会(IDSA)联合成立的HCV指导小组的工作。该小组依托其深厚的专业知识和广泛覆盖的网站平台,致力于推进HCV消除计划^[1]。本文分析当前美国关于HCV消除工作的研究进展、面临的障碍以及潜在的解决方案,强调政府提供的资源与HCV指导小组计划开展的工作对美国实现HCV消除目标的助力。

关键词: 丙型肝炎病毒, 消除丙型肝炎, 丙型肝炎指导小组, 筛查, 微消除

宋曼茜, 饶慧瑛. 美国丙型肝炎消除计划的障碍与机遇[J]. 肝脏, 2024, 29(7): 759-762.

/ 推荐

参考文献

[1] Lo Re V III, Price J C, Schmitt S, et al. The Obstacle is the Way: Finding a Path to Hepatitis C Elimination[J]. Clin Infect Dis, 2024: ciae231.
[2] Cui F, Blach S, Mingiedi C M, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C[J]. Lancet Gastroenterol Hepatol, 2023, 8(4): 332-342.
[3] Thiagarajan P, Ryder S D. The hepatitis C revolution part 1: antiviral treatment options[J]. Curr Opin in Infect Dis, 2015, 28(6): 563.
[4] Keating G M. Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C[J]. Drugs, 2015, 75(6): 675-685.
[5] Bhattacharya D, Aronsohn A, Price J. Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases- Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection[J]. Clin Infect Dis,2023.
[6] Sivakumar A, Madden L, DiDomizio E, et al. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients[J]. Int J Drug Policy,2022, 101: 103570.
[7] White House budget includes ambitious push to eliminate hepatitis C[EB/OL]. /2024-07-07. https://www.science.org/content/article/white-house-budget-includes-ambitious-push-eliminate-hepatitis-c.
[8] Fleurence R L, Collins F S. A National Hepatitis C Elimination Program in the United States: A Historic Opportunity[J]. JAMA, 2023, 329(15): 1251-1252.
[9] Hajarizadeh B, Grebely J, Dore G J. Epidemiology and natural history of HCV infection[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9): 553-562.
[10] Ferrante N D, Newcomb C W, Forde K A, et al. The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population[J]. Open Forum Infecti Dis, 2022, 9(9): ofac445.
[11] Cartwright E J. Updated Operational Guidance for Implementing CDC's Recommendations on Testing for Hepatitis C Virus Infection[J]. MMWR Morb Mortal Wkly Rep,2023,72(28):766-768.
[12] Gowda C, Lott S, Grigorian M, et al. Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study[J]. Open Forum Infectious Diseases, 2018, 5(6): ofy076.
[13] Grebely J, Haire B, Taylor L E, et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?[J]. J Hepatol, 2015, 63(4): 779-782.
[14] Saine M E, Szymczak J E, Moore T M, et al. The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection[J]. PLoS One, 2021, 16(10): e0258143.
[15] Goodyear T, Brown H, Browne AJ, et al. “Stigma is where the harm comes from”: Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs[J]. Int J Drug Policy, 2021, 96: 103238.
[16] Blach S, Brown K A, Brown R S, et al. Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress[J]. J Infect Public Health, 2023, 16(1): 64-70.
[17] Fourati S, Feld J J, Chevaliez S, et al. Approaches for simplified HCV diagnostic algorithms[J]. J Int AIDS Soc, 2018, 21(S2): e25058.
[18] Mavilia M G, Wu G Y. HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation[J]. J Clin Transl Hepatol, 2018, 6(3): 296-305.
[19] Majethia S, Lee I H, Chastek B, et al. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C[J].J Manag Care Spec Pharm,2022,28(1):48-57.
[20] Klaman S L, Godino J G, Northrup A, et al. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol[J]. BMC Infect Dis, 2024, 24(1): 105.
[21] Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework[J]. Liver Int, 2019, 39(1): 20-30.
[22] Hagan H, Pouget E R, Des Jarlais D C. A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs[J]. J Infect Dis, 2011, 204(1): 74-83.
[23] Louisiana's Journey Toward Eliminating Hepatitis C | Health Affairs[EB/OL]. /2024-07-10. https://www.healthaffairs.org/content/forefront/louisiana-s-journey-toward-eliminating-hepatitis-c.
[24] Huang C F, Chen G J, Hung C C, et al. HCV Microelimination for High-risk Special Populations[J]. J Infect Dis, 2023, 228(Supplement_3): S168-S179.